Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.

about

Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.

Item

http://www.wikidata.org/entity/Q37773249

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Optimal application of antibod ...... andards and future strategies.

@en

Optimal application of antibod ...... andards and future strategies.

@nl

type

Item

label

Optimal application of antibod ...... andards and future strategies.

@en

Optimal application of antibod ...... andards and future strategies.

@nl

prefLabel

Optimal application of antibod ...... andards and future strategies.

@en

Optimal application of antibod ...... andards and future strategies.

@nl

P1476

Optimal application of antibod ...... andards and future strategies.

@en

P2093

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

Till Seiler

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hiddemann

http://www.w3.org/2001/XMLSchema#string

P2860

Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

From the bench to the bedside: ways to improve rituximab efficacy.

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

P304

1015-1024

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.09.55

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20635916

http://www.w3.org/2001/XMLSchema#string